BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 12415476)

  • 1. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit.
    Johnson AP; Tysall L; Stockdale MV; Woodford N; Kaufmann ME; Warner M; Livermore DM; Asboth F; Allerberger FJ
    Eur J Clin Microbiol Infect Dis; 2002 Oct; 21(10):751-4. PubMed ID: 12415476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive care unit dissemination of multiple clones of linezolid-resistant Enterococcus faecalis and Enterococcus faecium.
    Ntokou E; Stathopoulos C; Kristo I; Dimitroulia E; Labrou M; Vasdeki A; Makris D; Zakynthinos E; Tsakris A; Pournaras S
    J Antimicrob Chemother; 2012 Aug; 67(8):1819-23. PubMed ID: 22532462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection.
    Seedat J; Zick G; Klare I; Konstabel C; Weiler N; Sahly H
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4217-9. PubMed ID: 16982791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nosocomial outbreak of linezolid-resistant Enterococcus faecalis infection in a tertiary care hospital.
    Gómez-Gil R; Romero-Gómez MP; García-Arias A; Ubeda MG; Busselo MS; Cisterna R; Gutiérrez-Altés A; Mingorance J
    Diagn Microbiol Infect Dis; 2009 Oct; 65(2):175-9. PubMed ID: 19717261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage.
    Bonora MG; Solbiati M; Stepan E; Zorzi A; Luzzani A; Catania MR; Fontana R
    J Clin Microbiol; 2006 Mar; 44(3):1153-5. PubMed ID: 16517918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linezolid-resistant Enterococcus faecium and Enterococcus faecalis isolated from a septic patient: report of first isolates in Germany.
    Halle E; Padberg J; Rosseau S; Klare I; Werner G; Witte W
    Infection; 2004 Jun; 32(3):182-3. PubMed ID: 15188081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vancomycin resistant enterococci in Austria].
    Allerberger F; Lass-Flörl C; Dierich MP; Hirschl AM; Presterl E; Haas G; Klare I; Witte W
    Wien Klin Wochenschr; 1997 May; 109(9):312-20. PubMed ID: 9265389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linezolid-resistant enterococci in Greece: epidemiological characteristics.
    Spiliopoulou I; Damani A; Chini V; Zerva L; Kolonitsiou F; Anastassiou ED; Petinaki E
    Chemotherapy; 2011; 57(3):181-5. PubMed ID: 21474928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linezolid-resistant clinical isolates of enterococci and Staphylococcus cohnii from a multicentre study in China: molecular epidemiology and resistance mechanisms.
    Chen H; Wu W; Ni M; Liu Y; Zhang J; Xia F; He W; Wang Q; Wang Z; Cao B; Wang H
    Int J Antimicrob Agents; 2013 Oct; 42(4):317-21. PubMed ID: 23880167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro analysis of resistance selection by linezolid in vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium.
    Allen GP; Bierman BC
    Int J Antimicrob Agents; 2009 Jul; 34(1):21-4. PubMed ID: 19243921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid.
    Rahim S; Pillai SK; Gold HS; Venkataraman L; Inglima K; Press RA
    Clin Infect Dis; 2003 Jun; 36(11):E146-8. PubMed ID: 12766857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colonisation with vancomycin- and linezolid-resistant Enterococcus faecium in a university hospital: molecular epidemiology and risk factor analysis.
    Souli M; Sakka V; Galani I; Antoniadou A; Galani L; Siafakas N; Zerva L; Fytrou H; Tsiodras S; Giamarellou H
    Int J Antimicrob Agents; 2009 Feb; 33(2):137-42. PubMed ID: 19013056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center.
    Dobbs TE; Patel M; Waites KB; Moser SA; Stamm AM; Hoesley CJ
    J Clin Microbiol; 2006 Sep; 44(9):3368-70. PubMed ID: 16954275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report.
    Swoboda S; Fritz S; Martignoni ME; Feldhues RA; Hoppe-Tichy T; Buchler MW; Geiss HK
    J Antimicrob Chemother; 2005 Oct; 56(4):787-9. PubMed ID: 16143710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of fosfomycin tromethamine and linezolid against vancomycin-resistant Enterococcus faecium isolates.
    Cilli F; Pullukcu H; Aydemir S; Sipahi OR; Tasbakan M; Turhan A; Ulusoy S
    Int J Antimicrob Agents; 2008 Mar; 31(3):297-8. PubMed ID: 18180144
    [No Abstract]   [Full Text] [Related]  

  • 16. Nosocomial superinfections due to linezolid-resistant Enterococcus faecalis: evidence for a gene dosage effect on linezolid MICs.
    Ruggero KA; Schroeder LK; Schreckenberger PC; Mankin AS; Quinn JP
    Diagn Microbiol Infect Dis; 2003 Nov; 47(3):511-3. PubMed ID: 14596970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical impact of linezolid susceptibility reporting in patients with vancomycin-resistant enterococci.
    Scheetz MH; Qi C; Noskin GA; Warren JR; Postelnick MJ; Malczynski M; Huang J; Zembower TR
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):407-13. PubMed ID: 16930924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium.
    Herrero IA; Issa NC; Patel R
    N Engl J Med; 2002 Mar; 346(11):867-9. PubMed ID: 11893808
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium.
    Pai MP; Rodvold KA; Schreckenberger PC; Gonzales RD; Petrolatti JM; Quinn JP
    Clin Infect Dis; 2002 Nov; 35(10):1269-72. PubMed ID: 12410489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers).
    Jones RN; Fritsche TR; Sader HS; Ross JE
    Diagn Microbiol Infect Dis; 2007 Nov; 59(3):309-17. PubMed ID: 17720350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.